FeesSafety
Pluang+

MAIA Biotechnology reports 88% disease control in Phase 2 lung cancer trial with novel therapy.

Market News
17 Nov 2026, 15:45 WIB
GlobeNewsWire
View Source
Bullish
MAIA Biotechnology reports 88% disease control in Phase 2 lung cancer trial with novel therapy.

MAIA Biotechnology announced interim results from its Phase 2 THIO-101 trial showing an 88% disease control rate in advanced non-small cell lung cancer patients resistant to prior treatments. The trial tests ateganosine, a novel telomere-targeting agent, followed by cemiplimab to enhance immune response. These results, consistent across expanded patient groups, suggest strong potential for accelerated FDA approval. MAIA is also progressing a pivotal Phase 3 trial with interim analysis expected in 2027.

MAIA Biotechnology's Phase 2 THIO-101 trial interim results are presented here with Pluang's health sector market data as of Nov 17, 2026 20:04 WIB. Of 150 priced US health stocks on Pluang, 49 rose and 91 fell today. Notable movers include Humana Inc (HUM) at USD 445.87 with a 3.31% decline and 100% buy order activity, UnitedHealth Group Inc (UNH) at USD 401.50 down 2.55% with 77% buy orders, and CVS Health Corp (CVS) at USD 86.39 down 2.48% with predominantly sell orders. The most notable figure is Humana's full buy-side order activity despite its price drop.

More News

Adagene and City of Hope launch Phase 1 trial for new colorectal cancer combo therapy.

Adagene and City of Hope launch Phase 1 trial for new colorectal cancer combo therapy.

Adagene Inc. and City of Hope have started a Phase 1 clinical trial testing a new combination therapy for metastatic colorectal cancer patients resistant to standard treatments. The trial evaluates two experimental drugs, ivonescimab and muzastotug (...

Others
Bullish
1 hour ago
Provident Bank appoints three leaders to boost commercial banking growth and services.

Provident Bank appoints three leaders to boost commercial banking growth and services.

Provident Bank announced three key leadership appointments to strengthen its Commercial Banking division. Edward Galan will lead Middle Market Lending, Dawn Scocco will manage portfolio and credit risk, and John Maio will head Treasury Management Ser...

Market News
Bullish
1 hour ago
RoyaLand launches its first mobile game Palazzo Chronicles: Match 3 on Google Play.

RoyaLand launches its first mobile game Palazzo Chronicles: Match 3 on Google Play.

RoyaLand Company Ltd. has released its first mobile game, Palazzo Chronicles: Match 3, on the Google Play Store. The free-to-play match-3 puzzle game features over 270 levels where players restore a royal palace set in Risorgimento Italy. This launch...

Others
Bullish
1 hour ago
Atiq Khan joins Dune as Director of Engineering to lead real-time onchain market data development.

Atiq Khan joins Dune as Director of Engineering to lead real-time onchain market data development.

Atiq Khan, with over 25 years in financial technology including roles at Goldman Sachs and Coinbase, has joined Dune as Director of Engineering. He will lead the engineering efforts behind Dune Market Data Feeds, which provide real-time trade and liq...

Others
Bullish
1 hour ago
BlackRock increases voting rights in ICG PLC to 5.16% as of November 13, 2026

BlackRock increases voting rights in ICG PLC to 5.16% as of November 13, 2026

BlackRock, Inc. has increased its total voting rights in ICG PLC to 5.16% as of November 13, 2026, up from 5.17% previously reported. This includes 5.08% voting rights attached to shares and 0.08% through financial instruments. The notification was o...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App